HERZLIA, Israel--(BUSINESS WIRE)--Tissera, Inc. (OTCBB: TSSR) reports encouraging preliminary results of its large animal diabetic model experiments of pancreatic xenotransplantation, designed for the future treatment of insulin-dependent (type I) diabetes mellitus.
